Short answer
Janux Therapeutics, Inc. (JANX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
Janux Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $21.6M, or $0.34 per share, improved from $24.3M, or $0.39, year over year
- Cash, equivalents and short-term investments $945.7M, down from $966.6M at December 31, 2025, supporting multiple clinical programs
- JANX013 combination trial with JANX007 reached first-patient dosing, expanding Janux’s clinical pipeline in mCRPC
- JANX011 initial healthy-volunteer data scheduled for November 9, the first clinical readout for its ARM platform
- Collaboration revenue $9.3M in Q3, while R&D spending declined to $30.6M from $34.6M year over year
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Janux Therapeutics, Inc. 8-K filings
Get the next JANX 8-K as it lands
Follow JANX for push alerts, or ask the research agent what this filing means.